TUSTIN, Calif., May 26 /PRNewswire/ -- Frank J. Kiesner, Oncotech's President and Chief Executive Officer, announced today that Michael Nobel, Ph.D., Chairman of the Board of the Nobel Family Society, has joined the company's Board of Directors. The addition of Dr. Nobel, a visionary in social affairs and global healthcare, allows Oncotech to strengthen its leadership position in the field of individualizing cancer patient care.
Dr. Nobel received his Ph.D. from the University of Lausanne. Dr. Nobel has received numerous citations and awards including the prestigious Gandhi, King, Ikeda Award from Morehouse College in Atlanta (2002) and the Paul Harris Fellowship Award presented by Rotary International (1997). He has served as a consultant to the United Nations Social Affairs Division and the United Nations Educational Scientific and Cultural Organization (UNESCO). Dr. Nobel has extensive experience in healthcare and is currently CEO of a group of companies that provide diagnostic imaging services.
Dr. Nobel commented, "I have a long standing interest in new technologies that can improve healthcare on a global basis." Dr. Nobel further stated, "Oncotech has the technologies to do this. I am excited to assist Oncotech to improve cancer care in a genomic era."
Frank J. Kiesner, President and CEO of Oncotech commented, "Dr. Nobel is an accomplished visionary in global health issues and is dedicated to improving the welfare of humanity. His knowledge, enthusiasm, and quest for improvement in healthcare will be of immeasurable assistance to Oncotech."
Dr. Nobel joins Oncotech's distinguished board which includes Dr. Vincent De Vita, former Director of the National Cancer Institute; Dr. Bruce Chabner, Director of the Cancer Center at Massachusetts General Hospital; and Dr. Trevor Powles, former Head of the Breast Unit at the Royal Marsden Hospital, London.
Oncotech is privileged to have Dr. Nobel assisting in the future direction of the Company. He will bring an extraordinary amount of knowledge and experience to Oncotech which will ensure that the Company will fulfill its mission to improve the cancer patient's outcome, survival, and quality of life.
Oncotech is a company dedicated to improving the survival and quality of life of cancer patients through its molecular oncology testing services as well as through genomic research leading to the discovery and development of new pharmaceutical products. Oncotech provides testing services to over one thousand hospitals in the U.S. and works with major pharmaceutical companies throughout the world to assist them in the development of new targeted drugs. Oncotech is a market leader in the field of in vitro drug resistance and therapy selection testing. More information on the company is available at http://www.oncotech.com/.